STOCK TITAN

[Form 3] AMARIN CORP PLC\UK Initial Statement of Beneficial Ownership

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
3
Rhea-AI Filing Summary

Amarin Corporation plc (AMRN) — Initial insider ownership filed. The company’s EVP and Chief Operating Officer filed a Form 3 as of 10/17/2025, reporting 7,950 American Depositary Shares (ADS) held directly.

Reported derivative holdings include Restricted Stock Units covering 6,740, 5,800, and 7,376 ADS, and stock options for 33,193 ADS at $12.4 expiring 01/10/2035, 20,900 ADS at $24.2 expiring 02/01/2034, 13,480 ADS at $36 expiring 02/21/2033, and 5,000 ADS at $29 expiring 06/01/2032. The filing notes an April 11, 2025 ADS ratio change where 1 ADS represents 20 Ordinary Shares, with equity awards adjusted accordingly. RSU and option grants vest on schedules described, generally in annual or quarterly tranches over 18 months to four years.

Amarin Corporation plc (AMRN) — Initial insider ownership filed. L'Executive Vice President e Chief Operating Officer dell'azienda ha presentato un Form 3 al 17/10/2025, riportando 7.950 American Depositary Shares (ADS) detenute direttamente.

Le partecipazioni derivate riportate includono Restricted Stock Units che coprono 6.740, 5.800 e 7.376 ADS, e stock options per 33.193 ADS a 12,4$ in scadenza 01/10/2035, 20.900 ADS a 24,2$ in scadenza 02/01/2034, 13.480 ADS a 36$ in scadenza 02/21/2033, e 5.000 ADS a 29$ in scadenza 06/01/2032. La presentazione indica un cambiamento del rapporto ADS il 11 aprile 2025 dove 1 ADS rappresenta 20 azioni ordinarie, con premi azionari adeguati di conseguenza. Le assegnazioni RSU e le opzioni si vanno a consolidare secondo piani descritti, generalmente in tranche annuali o trimestrali nell’arco di 18 mesi a quattro anni.

Amarin Corporation plc (AMRN) — Oferta inicial de propiedad de insider. La vicepresidenta ejecutiva y directora de operaciones de la empresa presentó un Formulario 3 al 17/10/2025, informando 7.950 American Depositary Shares (ADS) poseídas directamente.

Las participaciones derivadas informadas incluyen Restricted Stock Units que cubren 6.740, 5.800 y 7.376 ADS, y opciones sobre acciones para 33.193 ADS a $12.4 con vencimiento 01/10/2035, 20.900 ADS a $24.2 con vencimiento 02/01/2034, 13.480 ADS a $36 con vencimiento 02/21/2033, y 5.000 ADS a $29 con vencimiento 06/01/2032. El archivo señala un cambio de ratio de ADS el 11 de abril de 2025 donde 1 ADS representa 20 acciones ordinarias, los premios de capital se ajustaron en consecuencia. Las concesiones de RSU y de opciones se vesting según los calendarios descritos, generalmente en tramos anuales o trimestrales durante 18 meses a cuatro años.

Amarin Corporation plc (AMRN) — 초기 내부자 소유 발표. 회사의 EVP 겸 최고운영책임자(COO)가 2025년 10월 17일자 Form 3를 제출하여 7,950 American Depositary Shares (ADS)를 직접 보유하고 있다고 보고했습니다.

보고된 파생 보유에는 6,740, 5,800, 7,376 ADS를 커버하는 Restricted Stock Units와 33,193 ADS의 주식매수선택권이 $12.4에 만료일 2035/01/10, 20,900 ADS의 주식매수선택권이 $24.2에 만료일 2034/02/01, 13,480 ADS의 주식매수선택권이 $36에 만료일 2033/02/21, 5,000 ADS의 주식매수선택권이 $29에 만료일 2032/06/01. 제출서에는 2025년 4월 11일 ADS 비율 변경이 언급되었으며 1 ADS가 20주 보통주를 나타냄, 따라서 주식보상이 그에 따라 조정되었습니다. RSU 및 옵션 부여는 일반적으로 18개월에서 4년간 매년 또는 분기별로 vest 됩니다.

Amarin Corporation plc (AMRN) — Déclaration de détention initiale des initiés. Le vice-président exécutif et directeur des opérations de l'entreprise a déposé un Form 3 au 17/10/2025, indiquant 7 950 American Depositary Shares (ADS) détenues directement.

Les positions dérivées déclarées incluent des Restricted Stock Units couvrant 6 740, 5 800 et 7 376 ADS, et des options sur actions pour 33 193 ADS à 12,4 $ échéant le 01/10/2035, 20 900 ADS à 24,2 $ échéant le 01/02/2034, 13 480 ADS à 36 $ échéant le 21/02/2033, et 5 000 ADS à 29 $ échéant le 01/06/2032. Le dossier note un changement de ratio ADS au 11 avril 2025 où 1 ADS représente 20 actions ordinaires, les attributions d’actions et d’options étant ajustées en conséquence. Les grants RSU et les options vestent selon des plannings décrits, généralement en tranches annuelles ou trimestrielles sur 18 mois à quatre ans.

Amarin Corporation plc (AMRN) — Erster Insider-Eigentum gemeldet. Der Executive Vice President und Chief Operating Officer des Unternehmens hat am 17.10.2025 ein Form 3 eingereicht und meldete 7.950 American Depositary Shares (ADS) direkt gehalten.

Zu den berichteten derivativen Beständen gehören Restricted Stock Units über 6.740, 5.800 und 7.376 ADS sowie Aktienoptionen für 33.193 ADS zu 12,4 $ fällig am 01.10.2035, 20.900 ADS zu 24,2 $ fällig am 01.02.2034, 13.480 ADS zu 36 $ fällig am 21.02.2033 und 5.000 ADS zu 29 $ fällig am 01.06.2032. Der Bericht erwähnt eine Änderung des ADS-Verhältnisses zum 11.04.2025, wobei 1 ADS 20 Stammaktien entspricht, wodurch Aktienvergaben entsprechend angepasst wurden. RSU- und Optionszuteilungen vesten gemäß den beschriebenen Zeitplänen, typischerweise in jährlichen oder vierteljährlichen Tranchen über 18 Monate bis vier Jahre.

Amarin Corporation plc (AMRN) — تم تقديم ملكية داخلية أولية. قدم نائب الرئيس التنفيذي ومدير العمليات للشركة نموذج 3 بتاريخ 17/10/2025، مُبلغًا عن 7,950 American Depositary Shares (ADS) مملوكة مباشرة.

تشمل الحيازات المشتقة المبلغ عنها وحدات الأسهم المقيدة التي تغطي 6,740، 5,800، و7,376 ADS، وخيارات أسهم لـ 33,193 ADS بسعر $12.4 تنتهي صلاحيته في 01/10/2035، و20,900 ADS بسعر $24.2 تنتهي صلاحيته في 02/01/2034، و13,480 ADS بسعر $36 تنتهي صلاحيته في 02/21/2033، و5,000 ADS بسعر $29 تنتهي صلاحيته في 06/01/2032. وتشير الوثيقة إلى تغيير نسبة ADS في 11 أبريل 2025 حيث 1 ADS يمثل 20 سهماً عاديًا، مع تعديل جوائز الأسهم وفقًا لذلك. تؤجل منح RSU وخيارات حتى عادة في دفعات سنوية أو ربع سنوية على مدى 18 شهرًا إلى أربع سنوات.

Positive
  • None.
Negative
  • None.

Amarin Corporation plc (AMRN) — Initial insider ownership filed. L'Executive Vice President e Chief Operating Officer dell'azienda ha presentato un Form 3 al 17/10/2025, riportando 7.950 American Depositary Shares (ADS) detenute direttamente.

Le partecipazioni derivate riportate includono Restricted Stock Units che coprono 6.740, 5.800 e 7.376 ADS, e stock options per 33.193 ADS a 12,4$ in scadenza 01/10/2035, 20.900 ADS a 24,2$ in scadenza 02/01/2034, 13.480 ADS a 36$ in scadenza 02/21/2033, e 5.000 ADS a 29$ in scadenza 06/01/2032. La presentazione indica un cambiamento del rapporto ADS il 11 aprile 2025 dove 1 ADS rappresenta 20 azioni ordinarie, con premi azionari adeguati di conseguenza. Le assegnazioni RSU e le opzioni si vanno a consolidare secondo piani descritti, generalmente in tranche annuali o trimestrali nell’arco di 18 mesi a quattro anni.

Amarin Corporation plc (AMRN) — Oferta inicial de propiedad de insider. La vicepresidenta ejecutiva y directora de operaciones de la empresa presentó un Formulario 3 al 17/10/2025, informando 7.950 American Depositary Shares (ADS) poseídas directamente.

Las participaciones derivadas informadas incluyen Restricted Stock Units que cubren 6.740, 5.800 y 7.376 ADS, y opciones sobre acciones para 33.193 ADS a $12.4 con vencimiento 01/10/2035, 20.900 ADS a $24.2 con vencimiento 02/01/2034, 13.480 ADS a $36 con vencimiento 02/21/2033, y 5.000 ADS a $29 con vencimiento 06/01/2032. El archivo señala un cambio de ratio de ADS el 11 de abril de 2025 donde 1 ADS representa 20 acciones ordinarias, los premios de capital se ajustaron en consecuencia. Las concesiones de RSU y de opciones se vesting según los calendarios descritos, generalmente en tramos anuales o trimestrales durante 18 meses a cuatro años.

Amarin Corporation plc (AMRN) — 초기 내부자 소유 발표. 회사의 EVP 겸 최고운영책임자(COO)가 2025년 10월 17일자 Form 3를 제출하여 7,950 American Depositary Shares (ADS)를 직접 보유하고 있다고 보고했습니다.

보고된 파생 보유에는 6,740, 5,800, 7,376 ADS를 커버하는 Restricted Stock Units와 33,193 ADS의 주식매수선택권이 $12.4에 만료일 2035/01/10, 20,900 ADS의 주식매수선택권이 $24.2에 만료일 2034/02/01, 13,480 ADS의 주식매수선택권이 $36에 만료일 2033/02/21, 5,000 ADS의 주식매수선택권이 $29에 만료일 2032/06/01. 제출서에는 2025년 4월 11일 ADS 비율 변경이 언급되었으며 1 ADS가 20주 보통주를 나타냄, 따라서 주식보상이 그에 따라 조정되었습니다. RSU 및 옵션 부여는 일반적으로 18개월에서 4년간 매년 또는 분기별로 vest 됩니다.

Amarin Corporation plc (AMRN) — Déclaration de détention initiale des initiés. Le vice-président exécutif et directeur des opérations de l'entreprise a déposé un Form 3 au 17/10/2025, indiquant 7 950 American Depositary Shares (ADS) détenues directement.

Les positions dérivées déclarées incluent des Restricted Stock Units couvrant 6 740, 5 800 et 7 376 ADS, et des options sur actions pour 33 193 ADS à 12,4 $ échéant le 01/10/2035, 20 900 ADS à 24,2 $ échéant le 01/02/2034, 13 480 ADS à 36 $ échéant le 21/02/2033, et 5 000 ADS à 29 $ échéant le 01/06/2032. Le dossier note un changement de ratio ADS au 11 avril 2025 où 1 ADS représente 20 actions ordinaires, les attributions d’actions et d’options étant ajustées en conséquence. Les grants RSU et les options vestent selon des plannings décrits, généralement en tranches annuelles ou trimestrielles sur 18 mois à quatre ans.

Amarin Corporation plc (AMRN) — Erster Insider-Eigentum gemeldet. Der Executive Vice President und Chief Operating Officer des Unternehmens hat am 17.10.2025 ein Form 3 eingereicht und meldete 7.950 American Depositary Shares (ADS) direkt gehalten.

Zu den berichteten derivativen Beständen gehören Restricted Stock Units über 6.740, 5.800 und 7.376 ADS sowie Aktienoptionen für 33.193 ADS zu 12,4 $ fällig am 01.10.2035, 20.900 ADS zu 24,2 $ fällig am 01.02.2034, 13.480 ADS zu 36 $ fällig am 21.02.2033 und 5.000 ADS zu 29 $ fällig am 01.06.2032. Der Bericht erwähnt eine Änderung des ADS-Verhältnisses zum 11.04.2025, wobei 1 ADS 20 Stammaktien entspricht, wodurch Aktienvergaben entsprechend angepasst wurden. RSU- und Optionszuteilungen vesten gemäß den beschriebenen Zeitplänen, typischerweise in jährlichen oder vierteljährlichen Tranchen über 18 Monate bis vier Jahre.

Amarin Corporation plc (AMRN) — تم تقديم ملكية داخلية أولية. قدم نائب الرئيس التنفيذي ومدير العمليات للشركة نموذج 3 بتاريخ 17/10/2025، مُبلغًا عن 7,950 American Depositary Shares (ADS) مملوكة مباشرة.

تشمل الحيازات المشتقة المبلغ عنها وحدات الأسهم المقيدة التي تغطي 6,740، 5,800، و7,376 ADS، وخيارات أسهم لـ 33,193 ADS بسعر $12.4 تنتهي صلاحيته في 01/10/2035، و20,900 ADS بسعر $24.2 تنتهي صلاحيته في 02/01/2034، و13,480 ADS بسعر $36 تنتهي صلاحيته في 02/21/2033، و5,000 ADS بسعر $29 تنتهي صلاحيته في 06/01/2032. وتشير الوثيقة إلى تغيير نسبة ADS في 11 أبريل 2025 حيث 1 ADS يمثل 20 سهماً عاديًا، مع تعديل جوائز الأسهم وفقًا لذلك. تؤجل منح RSU وخيارات حتى عادة في دفعات سنوية أو ربع سنوية على مدى 18 شهرًا إلى أربع سنوات.

SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
Keenan David Paul

(Last) (First) (Middle)
C/O AMARIN PHARMA, INC.
440 US HIGHWAY 22

(Street)
BRIDGEWATER NJ 08807

(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
10/17/2025
3. Issuer Name and Ticker or Trading Symbol
AMARIN CORP PLC\UK [ AMRN ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
EVP, Chief Operating Officer
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
American Depositary Share(1) 7,950 D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units(2) (3) (4) American Depositary Share(1) 6,740 $0 D
Restricted Stock Units(2) (5) (4) American Depositary Share(1) 5,800 $0 D
Restricted Stock Units(2) (6) (4) American Depositary Share(1) 7,376 $0 D
Stock Option (Right to Buy) (7) 01/10/2035 American Depositary Share(1) 33,193 $12.4(8) D
Stock Option (Right to Buy) (9) 02/01/2034 American Depositary Share(1) 20,900 $24.2(8) D
Stock Option (Right to Buy) (10) 02/21/2033 American Depositary Share(1) 13,480 $36(8) D
Stock Option (Right to Buy) (11) 06/01/2032 American Depositary Share(1) 5,000 $29(8) D
Explanation of Responses:
1. Effective April 11, 2025, the Issuer implemented a ratio change that one (1) American Depositary Share ("ADS") currently represents twenty (20) Ordinary Shares ("ADS Ratio Change"). Proportionate adjustments were made to the Issuer's outstanding equity awards. The amount of securities reported on this Form 3 reflect the ADS Ratio Change.
2. Each RSU represents a contingent right to receive twenty Ordinary Shares or cash in lieu thereof at the Issuer's discretion.
3. On February 21, 2023, the Reporting Person was granted 6,740 Restricted Stock Units ("RSUs") under the Amarin Corporation plc 2011 Stock Incentive Plan (the "Plan"). These RSUs vest in three equal installments on each of January 31, 2024, January 31, 2025 and January 31, 2026.
4. Not applicable.
5. On February 1, 2024, the Reporting Person was granted 5,800 RSUs under the Plan. These RSUs vest in three equal installments on each of January 31, 2025, January 31, 2026 and January 31, 2027.
6. On January 10, 2025, the Reporting Person was granted 7,376 RSUs under the Plan. These RSUs vest over eighteen months, with 50% to vest on the first anniversary of the grant date and the remaining balance to vest eighteen months after grant date.
7. On January 10, 2025, the Reporting Person was granted an option to purchase 33,193 Ordinary Shares under the Plan. The shares subject to this option shall vest and become exercisable over eighteen months, with 50% to vest on the first anniversary of the grant date and the remaining balance to vest eighteen months after grant date.
8. Grant price is set at the higher of (1) our nominal par value of 50 pence per share, as converted on date of grant, for which our Plan dictates under United Kingdom law, or (2) fair market value of stock price on the NASDAQ at close of business day.
9. On February 1, 2024, the Reporting Person was granted an option to purchase 20,900 Ordinary Shares under the Plan. The shares subject to this option shall vest and become exercisable over three years, with 33% to vest on the first anniversary of the grant date and the balance to vest ratably over the subsequent 8 calendar quarters on the last day of each April, July, October and January.
10. On February 21, 2023, the Reporting Person was granted an option to purchase 13,480 Ordinary Shares under the Plan. The shares subject to this option shall vest and become exercisable over three years, with 33% to vest on the first anniversary of the grant date and the balance to vest ratably over the subsequent 8 calendar quarters on the last day of each April, July, October and January.
11. On June 1, 2022, the Reporting Person was granted an option to purchase 5,000 Ordinary Shares under the Plan. The shares subject to this option shall vest and become exercisable over four years, with 25% to vest on the first anniversary of the grant date and the balance to vest ratably over the subsequent 12 calendar quarters on the last day of each April, July, October and January.
/s/ Jonathan Provoost, by power of attorney 10/31/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Amarin

NASDAQ:AMRN

AMRN Rankings

AMRN Latest News

AMRN Latest SEC Filings

AMRN Stock Data

341.00M
20.60M
1.88%
18.04%
2.06%
Drug Manufacturers - General
Pharmaceutical Preparations
Link
Ireland
DUBLIN 2